BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 15831237)

  • 1. Cost of temozolomide therapy and global care for recurrent malignant gliomas followed until death.
    Wasserfallen JB; Ostermann S; Leyvraz S; Stupp R
    Neuro Oncol; 2005 Apr; 7(2):189-95. PubMed ID: 15831237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Re-evaluation of the cost effectiveness of temozolomide for malignant gliomas in British Columbia.
    Mabasa VH; Taylor SC
    J Oncol Pharm Pract; 2006 Jun; 12(2):105-11. PubMed ID: 16984749
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Can we afford to add chemotherapy to radiotherapy for glioblastoma multiforme? Cost-identification analysis of concomitant and adjuvant treatment with temozolomide until patient death.
    Wasserfallen JB; Ostermann S; Pica A; Mirimanoff RO; Leyvraz S; Villemure JG; Stupp R
    Cancer; 2004 Nov; 101(9):2098-105. PubMed ID: 15389472
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of temozolomide for the treatment of newly diagnosed glioblastoma multiforme: a report from the EORTC 26981/22981 NCI-C CE3 Intergroup Study.
    Lamers LM; Stupp R; van den Bent MJ; Al MJ; Gorlia T; Wasserfallen JB; Mittmann N; Jin Seung S; Crott R; Uyl-de Groot CA;
    Cancer; 2008 Mar; 112(6):1337-44. PubMed ID: 18213621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic evaluation of temozolomide in the treatment of recurrent glioblastoma multiforme.
    Martikainen JA; Kivioja A; Hallinen T; Vihinen P
    Pharmacoeconomics; 2005; 23(8):803-15. PubMed ID: 16097842
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effectiveness and cost-effectiveness of temozolomide for the treatment of recurrent malignant glioma: a rapid and systematic review.
    Dinnes J; Cave C; Huang S; Major K; Milne R
    Health Technol Assess; 2001; 5(13):1-73. PubMed ID: 11359682
    [No Abstract]   [Full Text] [Related]  

  • 7. Temozolomide chemotherapy of patients with recurrent anaplastic astrocytomas and glioblastomas.
    Sipos L; Vitanovics D; Afra D
    Ideggyogy Sz; 2004 Nov; 57(11-12):394-9. PubMed ID: 15662767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The economics of temozolomide in brain cancer.
    Crott R
    Expert Opin Pharmacother; 2007 Aug; 8(12):1923-9. PubMed ID: 17696793
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of temozolomide for the treatment of newly diagnosed glioblastoma multiforme.
    Uyl-de Groot CA; Stupp R; van der Bent M
    Expert Rev Pharmacoecon Outcomes Res; 2009 Jun; 9(3):235-41. PubMed ID: 19527095
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Salvage chemotherapy with cyclophosphamide for recurrent, temozolomide-refractory glioblastoma multiforme.
    Chamberlain MC; Tsao-Wei DD
    Cancer; 2004 Mar; 100(6):1213-20. PubMed ID: 15022289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy.
    Grosu AL; Weber WA; Franz M; Stärk S; Piert M; Thamm R; Gumprecht H; Schwaiger M; Molls M; Nieder C
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):511-9. PubMed ID: 16168843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Favourable result for temozolomide in recurrent high-grade glioma].
    Taal W; van der Rijt CD; Sillevis Smitt PA; Kros JM; van Heuvel I; Enting RH; van den Bent MJ
    Ned Tijdschr Geneeskd; 2005 Jun; 149(25):1393-9. PubMed ID: 15997692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of glioblastoma: comparison of clinical practices and cost-effectiveness in two cohorts of patients (2008 versus 2004) diagnosed in a French university hospital.
    Diebold G; Ducray F; Henaine AM; Frappaz D; Guyotat J; Cartalat-Carel S; Breant V; Fouquet A; Aulagner G; Honnorat J; Armoiry X
    J Clin Pharm Ther; 2014 Dec; 39(6):642-8. PubMed ID: 25164371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Salvage therapy with bendamustine for temozolomide refractory recurrent anaplastic gliomas: a prospective phase II trial.
    Chamberlain MC; Colman H; Kim BT; Raizer J
    J Neurooncol; 2017 Feb; 131(3):507-516. PubMed ID: 28204914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Temozolomide treatment in glioma--experiences in two university hospitals in Finland.
    Mäenpää HO; Aaltonen K; Mäntylä R; Minn H
    Acta Oncol; 2004; 43(6):579-84. PubMed ID: 15370616
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Temozolomide in the treatment of recurrent malignant glioma.
    Chang SM; Theodosopoulos P; Lamborn K; Malec M; Rabbitt J; Page M; Prados MD
    Cancer; 2004 Feb; 100(3):605-11. PubMed ID: 14745879
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and economic evaluation of modulated electrohyperthermia concurrent to dose-dense temozolomide 21/28 days regimen in the treatment of recurrent glioblastoma: a retrospective analysis of a two-centre German cohort trial with systematic comparison and effect-to-treatment analysis.
    Roussakow SV
    BMJ Open; 2017 Nov; 7(11):e017387. PubMed ID: 29102988
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment of recidive malignant gliomas with temozolomide].
    Sipos L; Vitanovics D; Afra D
    Orv Hetil; 2002 May; 143(21):1201-4. PubMed ID: 12073541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of temozolomide in recurrent malignant gliomas.
    Gaya A; Rees J; Greenstein A; Stebbing J
    Cancer Treat Rev; 2002 Apr; 28(2):115-20. PubMed ID: 12297119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BCNU as second line therapy for recurrent high-grade glioma previously treated with Temozolomide.
    Rosenthal MA; Ashley DL; Cher L
    J Clin Neurosci; 2004 May; 11(4):374-5. PubMed ID: 15080950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.